| 000 | 00928 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250513173013.0 | ||
| 264 | 0 | _c19940728 | |
| 008 | 199407s 0 0 eng d | ||
| 022 | _a1170-7690 | ||
| 024 | 7 |
_a10.2165/00019053-199201060-00008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHenry, D A | |
| 245 | 0 | 0 |
_aShould indirect costs and benefits be included? _h[electronic resource] |
| 260 |
_bPharmacoEconomics _cJun 1992 |
||
| 300 |
_a462 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 | _aAbsenteeism |
| 650 | 0 | 4 | _aAustralia |
| 650 | 0 | 4 | _aCost of Illness |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 |
_aDyspepsia _xdrug therapy |
| 650 | 0 | 4 | _aEconomics, Pharmaceutical |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tPharmacoEconomics _gvol. 1 _gno. 6 _gp. 462 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00019053-199201060-00008 _zAvailable from publisher's website |
| 999 |
_c10106567 _d10106567 |
||